Typically, these effects are temporary and diminish as your body adapts
Dietary Intake by Patients Taking GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Narrative Review and Discussion of Research Needs. Obesity Pillars, vol
Once the target dose is reached, patients will likely move to a maintenance dose, which is then continued weekly to maintain weight loss and metabolic benefits
1,2 What it feels like People describe dysesthesia as burning, tingling, prickling, or a feeling of skin being unusually sensitive to clothing, water, or pressure
This will likely delay how soon you can access the medication, but many doctors are familiar with the process and will help patients navigate it
Retatrutide, sammenfatning af evidensgrundlaget Vi ved: Fase 2 viser 24,2% vgttab ved 12 mg over 48 uger (NEJM 2023) Fase 3 TRIUMPH-1, det pivotale fedme-studie (2.339 deltagere), viser 28,3% over 80 uger, op til 30,3% ved 104-ugers forlngelse hos BMI35 (forr 2026) Fase 3 TRIUMPH-4 (knartrose-substudie) viser 28,7% over 68 uger (december 2025) Bivirkningsprofilen ligner semaglutide og tirzepatide Leverfedtreduktion p op til 82% i substudie Markant HbA1c-reduktion ved type 2-diabetes (Lancet 2023) Vi ved endnu ikke: Langsigtet sikkerhed ud over 68 uger Prcis effekt p muskelmasse Kardiovaskulrt outcome (TRIUMPH-3 afventer) Effekt ved ophr Endelig pris og tilskudsstatus i Danmark Retatrutide og mental sundhed, en overset dimension Fedme og mental sundhed er tt forbundne
